96706 ⎘
Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links; Tripeptides with the first amino acid being neutral
Sub-classes:USE OF STEM CELL-BASED BIOSENSORS FOR REAL-TIME, NON-INVASIVE MONITORING OF NEURONAL DIFFERENTIATION
#2PIN1 TARGETING COMPOUNDS AND DEGRADERS AND METHODS THEREOF
#3METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS
#4PEPTIDE TAG AND TAGGED PROTEIN CONTAINING SAME
#5Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
#6Building blocks for stapled peptides
#7Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
#8Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
#9Supramolecular hydrogel of fMLF-based molecules and use thereof
#10HCV PROTEASE INHIBITORS AND USES THEREOF
#11Crystalline tripeptide epoxy ketone protease inhibitors
#12Method for producing a recombinant peptide and resultant peptide
#13Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
#14Versatile native chemical ligation technologies
#15HCV protease inhibitors
#16HCV protease inhibitors and uses thereof
#17Crystalline tripeptide epoxy ketone protease inhibitors
#18Crystalline tripeptide epoxy ketone protease inhibitors
#19HCV NS3 protease inhibitors
#20CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS
#21Anti-viral compounds
#22HCV protease inhibitors and uses thereof
#23MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS
#24Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
#25Spatially-defined macrocycles incorporating peptide bond surrogates
#26Process for making macrocyclic oximyl hepatitis C protease inhibitors
#27Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
#28Hydrazide-containing hepatitis C serine protease inhibitors
#29N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS
#30Process for preparing macrocyclic compounds
#31Hepatitis C virus inhibitors
#32Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
#33Hypoglycemic agent
#34Hypoglycemic agent
#35Hypoglycemic agent
#36Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
#37Method of treating interferon non-responders using HCV protease inhibitor
#38Macrocyclic peptides active against the hepatitis C virus
#39Substrates for TAFI (A)
#40Process for preparing macrocyclic compounds
#41Hepatitis C virus inhibitors
#42Composition for the treatment of infection by Flaviviridae viruses
#43Hypoglycemic agent
#44Spatially-defined macrocycles incorporating peptide bond surrogates
#45Macrocyclic inhibitors of hepatitis C virus NS3-serine protease
#46Tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases
#47Macrocyclic peptides active against the hepatitis C virus
#48Macrocyclic peptides active against the hepatitis C virus